Abstract 3368
Background
First-line therapy with pembrolizumab is the standard of care in locally advanced and metastatic non-small cell lung cancer (NSCLC) with a PD-L1 expression of ≥ 50%. However, efficacy results in patients with a PS ≥ 2, untreated brain metastases or permanent oral steroids are lacking.
Methods
Patients from six certified lung cancer centers in Berlin, Germany, presenting with stage III (non resectable, not suitable for chemoradiation) and IV NSCLC, with a PD-L1 expression of ≥ 50%, diagnosed or treated between January 1st, 2017 and December 31, 2017 were included in this retrospective study. Progression-free (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Cox regression analyses were used to identify prognostic factors for survival. Values are given as median (range).
Results
During the observation period, 128 patients fulfilled the inclusion criteria. Median age was 68.6 years (39 – 85), 76 patients were male (59.4%). Histology was predominantly non-squamous (68.8%). 31 patients (24.2%) had an initial PS of ≥ 2. Oral steroids for ≥2 weeks (equivalent daily doses of ≥ 10 mg of prednisolone during therapy with pembrolizumab) were prescribed to 34 patients (26.6%). Pembrolizumab was initiated in 24 patients with previously untreated brain metastases (18.8%). Within a follow-up of 13.0 months (95% CI, 10.5 – 15.4), a median of 9 cycles (1 – 38) were administered corresponding to a duration of treatment of 6.9 months (95% CI, 4.6 – 9.2). Therapy was still ongoing in 30 patients (23.4%). PFS was 9.4 months (95% CI, 4.8 – 14.1) with a duration of response of 11.9 months (95%CI, 8.4 – 15.4). OS reached 18.9 months (95% CI, NE – NE). A PS ≥ 2 was associated with a reduced OS (HR 0.43, 95% CI, 0.25 – 0.75, p = 0.003), no effects were noted for brain metastases and steroids.
Conclusions
Our data from real life practice in an all comer population demonstrate the efficacy of pembrolizumab in NSCLC with a PD-L1 expression of ≥ 50%. Despite a reduced survival in PS ≥ 2, the reached OS of 8.0 months is superior to historic cohorts with cytotoxic chemotherapy. Furthermore, OS was unchanged in case of untreated brain metastases or permanent steroids.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract